Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating.
BioNTech SE (NASDAQ:BNTX – Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $92.72, but opened at $90.09. BioNTech shares last traded at $92.49, with a volume of 481,363 shares trading hands. Analysts Set New Price Targets Several research firms recently commented on BNTX. HC Wainwright […]
BioNTech (NASDAQ:BNTX – Get Free Report) will announce its earnings results before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link. BioNTech (NASDAQ:BNTX – Get Free […]
BioNTech (NASDAQ:BNTX – Get Free Report) will be posting its quarterly earnings results before the market opens on Monday, May 6th. Analysts expect BioNTech to post earnings of ($0.45) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link. BioNTech (NASDAQ:BNTX – Get Free […]
BioNTech SE (NASDAQ:BNTX – Get Free Report) has been assigned an average rating of “Hold” from the ten ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and four have assigned a buy recommendation to the […]